Xintai He Biological purchases Lu Xiangyi’s centrifuge for its pharmaceutical project.
Release time:
2016-04-11
Overview:
Zhongzhu Group’s Xintaihe Bio-Investment has introduced and acquired cutting-edge biopharmaceutical technologies both domestically and internationally, and has also purchased centrifuge equipment worth 700,000 yuan from Shanghai Luxiangyi to support the research and development and production of new pharmaceuticals. The first-phase R&D project—the “Recombinant Modified Human Tumor Necrosis Factor Project”—is one of the most effective therapies worldwide for treating non-small cell lung cancer in combination with chemotherapy. This drug is classified as a Class I innovative biological medicine at the national level. The successful development of this drug will bring good news and hope to countless lung cancer patients.
The new cell therapy drug developed by Zhongzhu Group’s Xintaihe Bio will spearhead the future medical revolution, encompassing both tumor cell immunotherapy and stem cell therapy. Cell therapy involves transplanting or introducing into a patient’s body human cells that are either normal or genetically engineered. The newly introduced cells can replace damaged cells or exhibit enhanced immune-mediated cytotoxicity, thereby achieving the goal of disease treatment. Cell therapy has demonstrated increasingly high clinical value in the treatment of cancers, blood disorders, cardiovascular diseases, diabetes, Alzheimer’s disease, and other conditions.
Generally speaking, cell therapy encompasses two major categories: tumor cell immunotherapy and stem cell therapy. As American biologist George Daley once said: “If the 20th century was the age of pharmaceutical therapies, then the 21st century will be the age of cell therapies.” Biomedicine is bringing humanity one technological breakthrough after another at an astonishing pace. Whether it’s “tumor cell immunotherapy,” which harnesses a patient’s own cells to fight cancer, or “stem cell therapy,” which involves versatile “pluripotent” cells, both fields hold market potential worth hundreds of billions of U.S. dollars and represent crucial directions for the future development of medicine. However, the entire cell therapy industry—both domestically and internationally—remains in the early stages of research and development, and it will take some time to mature and grow.